Publications by authors named "Miriam Ferrara"

Claim this Profile
P
PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance.
Sara Pilotto, Lorenzo Belluomini, Federico Monaca, Michele Simbolo, Antonio Agostini, Miriam Grazia Ferrara

Ther Adv Med Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retroaortic left renal vein associated to variations of liver vasculature and biliary system in a patient submitted to total pancreatectomy.
Alessandro Fancellu, Mario Maiore, Lavinia Grasso, Miriam Ferrara, Alberto Porcu

Hepatobiliary Pancreat Dis Int· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors.
Miriam Grazia Ferrara, Lorenzo Belluomini, Annafrancesca Smimmo, Marco Sposito, Alice Avancini

Crit Rev Oncol Hematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis.
Lorenzo Belluomini, Sara Pilotto, Alice Avancini, Jessica Insolda, Marco Sposito, Miriam Grazia Ferrara

Semin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer.
Alessio Stefani, Geny Piro, Francesco Schietroma, Alessandro Strusi, Emanuele Vita, Miriam Grazia Ferrara

Front Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
Lorenzo Belluomini, Alice Avancini, Luca Pasqualin, Jessica Insolda, Marco Sposito, Miriam Grazia Ferrara

Expert Rev Anticancer Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?
Chiara Ciccarese, Roberto Iacovelli, Sebastiano Buti, Francesca Primi, Serena Astore, Miriam Grazia Ferrara

Anticancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.
Alessio Cortellini, Raffaele Giusti, Marco Filetti, Fabrizio Citarella, Vincenzo Adamo, Miriam Grazia Ferrara

J Hematol Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures.
Miriam Grazia Ferrara, Alessio Stefani, Sara Pilotto, Carmine Carbone, Emanuele Vita

Front Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned.
Lorenzo Belluomini, Silvia Teresa Riva, Michele Simbolo, Riccardo Nocini, Ilaria Trestini, Miriam Grazia Ferrara

Cells· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
Miriam Grazia Ferrara, Maurizio Martini, Ettore D'Argento, Chiara Forcella, Emanuele Vita

Clin Lung Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.
Lorenzo Belluomini, Alessandra Dodi, Alberto Caldart, Dzenete Kadrija, Marco Sposito, Miriam Grazia Ferrara

Transl Lung Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Vincenzo Di Noia, Ettore D'Argento, Sara Pilotto, Emanuele Vita, Miriam Grazia Ferrara

Cancer Immunol Immunother· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, Sergio Bracarda, Massimo Di Maio, Miriam G Ferrara

Eur J Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Alessio Cortellini, Katia Cannita, Marcello Tiseo, Diego L Cortinovis, Joachim G J V Aerts, Miriam G Ferrara

Eur J Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Alessio Cortellini, Massimo Di Maio, Olga Nigro, Alessandro Leonetti, Diego L Cortinovis, Miriam G Ferrara

J Immunother Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities.
Miriam Grazia Ferrara, Alessio Stefani, Michele Simbolo, Sara Pilotto, Maurizio Martini

Front Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, Federico Cappuzzo, Joachim G J V Aerts, Miriam G Ferrara

Cancer Immunol Immunother· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
Alessio Cortellini, Alex Friedlaender, Giuseppe L Banna, Giampiero Porzio, Melissa Bersanelli, Miriam G Ferrara

Clin Lung Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo, Emilio Bria, Giuseppe L Banna, Miriam G Ferrara

J Immunother Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.
Carmine Carbone, Geny Piro, Vincenzo Di Noia, Ettore D'Argento, Emanuele Vita, Miriam Grazia Ferrara

Mediators Inflamm· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Miriam Grazia Ferrara, Vincenzo Di Noia, Ettore D'Argento, Emanuele Vita, Paola Damiano

Cancers (Basel)· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survivors with immunotherapy in advanced NSCLC: is 'cure' within reach?
Sara Monteverdi, Emanuele Vita, Giulia Sartori, Miriam Grazia Ferrara, Ettore D'Argento

Transl Cancer Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Stress in Dogs Involved in Animal-Assisted Interventions.
Sara Corsetti, Miriam Ferrara, Eugenia Natoli

Animals (Basel)· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
Vincenzo Di Noia, Emanuele Vita, Miriam Ferrara, Antonia Strippoli, Michele Basso

Curr Treat Options Oncol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis